4,929 Shares in Natera, Inc. $NTRA Acquired by Evolve Private Wealth LLC

Evolve Private Wealth LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,929 shares of the medical research company’s stock, valued at approximately $1,338,000.

Other large investors have also recently modified their holdings of the company. Trust Co. of Vermont acquired a new stake in Natera in the second quarter valued at $26,000. Reflection Asset Management acquired a new position in Natera during the 4th quarter worth about $29,000. Elevation Wealth Partners LLC acquired a new position in Natera during the 2nd quarter worth about $30,000. Palladiem LLC bought a new stake in shares of Natera in the 4th quarter valued at about $31,000. Finally, Horizon Investments LLC bought a new stake in shares of Natera in the 3rd quarter valued at about $32,000. Institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent analyst reports. Guggenheim lifted their price objective on Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Leerink Partners set a $330.00 price target on shares of Natera in a report on Friday, August 7th. Morgan Stanley restated an “overweight” rating and issued a $355.00 price target on shares of Natera in a research report on Monday, August 10th. TD Cowen upped their price objective on shares of Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, UBS Group set a $260.00 price objective on shares of Natera in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $319.38.

Natera Price Performance

Shares of NTRA stock opened at $332.03 on Monday. The firm has a 50 day moving average of $274.24 and a 200-day moving average of $229.38. The company has a market cap of $47.86 billion, a price-to-earnings ratio of -244.14 and a beta of 1.51. Natera, Inc. has a 52 week low of $157.43 and a 52 week high of $333.56.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period last year, the business posted ($0.74) EPS. The firm’s revenue for the quarter was up 37.7% compared to the same quarter last year. Analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 3,076 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the completion of the sale, the chief executive officer owned 99,897 shares in the company, valued at $26,611,561.83. The trade was a 2.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16. Following the sale, the chief financial officer owned 51,637 shares of the company’s stock, valued at $14,159,898.14. This trade represents a 0.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 181,045 shares of company stock worth $41,330,968. 5.05% of the stock is currently owned by insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.